On June 11, 2025, Janux Therapeutics, Inc. held its Annual Meeting where stockholders elected new directors, ratified the accounting firm Ernst & Young LLP, and approved executive compensation with significant votes in favor. Out of 59,168,490 shares, over 56 million were present at the meeting, affirming strong shareholder engagement.